Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 5Active not recruiting 5Not yet recruiting 4Withdrawn 1Terminated 1Suspended 1

Sponsor Class

NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 79Bevacizumab 66Drug Therapy 65Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 61Radiotherapy 57Cyclophosphamide 55Gemcitabine 54pembrolizumab 53Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 37fludarabine 36Fluorouracil 35venetoclax 33Injections 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Surgical Procedures, Operative 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Hyaluronoglucosaminidase × 1 year × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡